XML 66 R48.htm IDEA: XBRL DOCUMENT v3.22.4
Fair Value Measurement (Tables)
12 Months Ended
Dec. 31, 2022
Summary of Financial Items Carried at Fair Value
Financial items carried at fair value as of December 31, 2022 and 2021 are classified in the tables below in one of the three categories described in note 1f:
 
 
  
December 31, 2022
 
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
 
  
(U.S. $ in millions)
 
Cash and cash equivalents:
  
  
  
  
Money markets
   $ 1,222        —          —        $ 1,222  
Cash, deposits and other
     1,579        —          —          1,579  
Investment in securities:
                                   
Equity securities
     9        —          —          9  
Other
     5        —          1        6  
Restricted cash
     33        —          —          33  
Derivatives:
                                   
Asset derivatives
:
O
ptions and forward contract
s

     —          29        —          29  
Liabilities derivatives:
                                —    
Options and forward contracts
     —          (101      —          (101
Bifurcated embedded derivatives
     —          —          §        —    
Contingent consideration*
     —          —          (153      (153
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 2,848      $ (73    $ (152    $ 2,624  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
§
Represents an amount less than 0.5 million
*
Contingent consideration represents liabilities recorded at fair value in connection with acquisitions..
 
 
  
December 31, 2021
 
 
  
Level 1
 
  
Level 2
 
  
Level 3
 
  
Total
 
 
  
(U.S. $ in millions)
 
Cash and cash equivalents:
  
  
  
  
Money markets
   $ 220        —          —        $ 220  
Cash, deposits and other
     1,945        —          —          1,945  
Investment in securities:
                                   
Equity securities
     18        —          —          18  
Other
     6        —          1        7  
Restricted cash
     33        —          —          33  
Derivatives:
                                   
Asset derivatives:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Options and forward contracts
     —          30        —          30  
Liability derivatives:
                                   
Options and forward contracts
     —          (23      —          (23
Bifurcated embedded derivatives
     —          —        §          —    
Contingent consideration*
     —          —          (176      (176
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
   $ 2,222      $ 7      $ (175    $ 2,054  
    
 
 
    
 
 
    
 
 
    
 
 
 
 
§
Represents an amount less than $0.5 million.
*
Contingent consideration represents liabilities recorded at fair value in connection with acquisitions.
Summary of Fair Value of Financial Liabilities Measured Using Level 3 Inputs
The following table summarizes the activity for those financial assets and liabilities where fair value measurements are estimated utilizing Level 3 inputs.
 
 
  
December 31,
2022
 
  
December 31,
2021
 
 
  
(U.S. $ in millions)
 
Fair value at the beginning of the period
   $ (175    $ (258
Redemption of debt securities
     —          (9
Bifurcated embedded derivatives
     §        §  
Adjustments to provisions for contingent consideration:
                 
Actavis Generics transaction
     (142      15  
Eagle transaction
     (21      (23
Settlement of contingent consideration:
                 
Actavis Generics transaction
     109        100  
Eagle transaction
     88        —    
Additional contingent consideration resulting from Novetide acquisition*
     (11      —    
    
 
 
    
 
 
 
Fair value at the end of the period
   $ (152    $ (175
    
 
 
    
 
 
 
 
§
Represents an amount less than 0.5 million. 
*
In January 2022, Teva acquired 100% ownership of Novetide Ltd. (“Novetide”), which was previously accounted for as “investment in associated companies”. This transaction was accounted for as a business combination. Total consideration for the transaction included cash and certain contingent royalty payments through 2034. As part of the transaction, Teva recognized a gain under “Share in (profits) losses of associated companies, net”, reflecting the difference between the book value of its investment in Novetide and its fair value as of the date Teva completed its acquisition.
Summary of Financial Instrument Measured on a Basis Other Than Fair Value
Financial instruments measured on a basis other than fair value consist of senior notes, sustainability-linked senior notes and convertible senior debentures (see note 9), and are presented in the below table in terms of fair value:
 
 
  
Estimated fair value*
 
 
  
December 31,
 
 
  
2022
 
  
2021
 
 
  
(U.S. $ in millions)
 
Senior notes and sustainability-linked senior notes included under senior notes and loans
   $ 16,694      $ 21,477  
Senior notes and convertible senior debentures included under short-term debt
     2,075        1,426  
    
 
 
    
 
 
 
Total
   $ 18,769      $ 22,903  
    
 
 
    
 
 
 
 
*
The fair value was estimated based on quoted market prices.